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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive airway disease characterised by neutrophilic
airway inflammation or bronchitis. Neutrophilic bronchitis is associated with both bacterial colonisation and lung function
decline and is common in exacerbations of COPD. Despite current available therapies to control inflammation, neutrophilic
bronchitis remains common. This study tested the hypothesis that azithromycin treatment, as an add-on to standard
medication, would significantly reduce airway neutrophil and neutrophils chemokine (CXCL8) levels, as well as bacterial
load. We conducted a randomised, double-blind, placebo-controlled study in COPD participants with stable neutrophilic
bronchitis.
Methods: Eligible participants (n = 30) were randomised to azithromycin 250 mg daily or placebo for 12 weeks in addition
to their standard respiratory medications. Sputum was induced at screening, randomisation and monthly for a 12 week
treatment period and processed for differential cell counts, CXCL8 and neutrophil elastase assessment. Quantitative
bacteriology was assessed in sputum samples at randomisation and the end of treatment visit. Severe exacerbations where
symptoms increased requiring unscheduled treatment were recorded during the 12 week treatment period and for 14
weeks following treatment. A sub-group of participants underwent chest computed tomography scans (n = 15).
Results: Nine participants with neutrophilic bronchitis had a potentially pathogenic bacteria isolated and the median total
bacterial load of all participants was 5.226107 cfu/mL. Azithromycin treatment resulted in a non-significant reduction in
sputum neutrophil proportion, CXCL8 levels and bacterial load. The mean severe exacerbation rate was 0.33 per person per
26 weeks in the azithromycin group compared to 0.93 exacerbations per person in the placebo group (incidence rate ratio
(95%CI): 0.37 (0.11,1.21), p = 0.062). For participants who underwent chest CT scans, no alterations were observed.
Conclusions: In stable COPD with neutrophilic bronchitis, add-on azithromycin therapy showed a trend to reduced severe
exacerbations sputum neutrophils, CXCL8 levels and bacterial load. Future studies with a larger sample size are warranted.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a major
global health issue. Airway inflammation is recognised as a key
element of COPD but its role in disease pathogenesis is poorly
understood. Persistent neutrophilic airway inflammation (neutrophilic
bronchitis) is a typical feature of COPD, which persists even after
the removal of stimuli such as tobacco smoke. Neutrophil function
in COPD is dysfunctional where clearance of antigens and micro-
organisms is impaired and persistent activation contributes to
further inflammation (neutrophil feedback cycle) and tissue
destruction [1,2].
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e105609
The presence of neutrophilic bronchitis in COPD is linked to
colonisation of the airways by bacteria and both airway
neutrophils and the presence of colonising bacteria are associated
with lung function decline [3,4]. We have previously shown that in
COPD, both sputum TLR2 gene expression and MMP9 protein
levels were independent contributors to the proportion of
neutrophils in sputum after correcting for age, smoking and
airflow obstruction [5]. The clinical consequences of neutrophilic
bronchitis include loss of lung function [6], however this feature
remains largely untreated in COPD.
Macrolide antibiotics such as azithromycin (AZM) accumulate
in host cells such as macrophages and neutrophils and have anti-
inflammatory effects. These include the inhibition of inflammatory
cytokines such as CXCL8 [7], reduced activation of neutrophils
and enhanced phagocytosis of apoptotic neutrophils [8]. Macro-
lides are effective anti-inflammatory agents in different diseases. In
cystic fibrosis, macrolides improve quality of life and prevent
deterioration of lung function [9], in asthma they reduce sputum
CXCL8 levels and improve quality of life [10] and in non-cystic
fibrosis bronchiectasis and COPD they reduce exacerbations
[11,12].
In COPD, macrolide therapy has been largely used as a
treatment for acute exacerbations [13]. Although the efficacy of
macrolides in preventing exacerbations in COPD is undisputed,
some participants experienced a large number of exacerbations
despite taking azithromycin [13]. One explanation for the
observed variability in the effectiveness of macrolides in preventing
exacerbations in COPD is the heterogeneity of airway inflamma-
tion in affected patients. The reduction in exacerbations in COPD
may be due to the suppression of neutrophilic inflammation and
bacterial load in the airways. If this is the case, then targeting
macrolides to COPD patients with neutrophilic bronchitis should
give optimal efficacy and minimise side effects by reducing
unnecessary exposure to therapy.
In this study we tested the hypothesis that azithromycin therapy
would reduce CXCL8 levels, bacterial load and, consequently,
neutrophilic inflammation in participants with neutrophilic
COPD. To do this we identified participants with symptomatic
COPD and stable neutrophilic bronchitis and determined the
effect of the addition of oral azithromycin on the intensity and
pattern of airway inflammation. This was achieved by measure-
ment of total cell counts, cellular differential and cytokine levels
present in induced sputum as well as alterations in bacterial load.
We also assessed the rate of severe exacerbations where
participants required unscheduled medical attention with treat-
ment of oral corticosteroids and/or antibiotics over a period of 26
weeks from the baseline visit. We found that treatment reduced
exacerbations but not neutrophilic bronchitis.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics statement
Participants gave written informed consent. The Hunter New
England Area Health Service and University of Newcastle Research
Human Ethics Committees approved the study (06/12/13/3.08
and H-2008-0272) and it was registered with the Australian New
Zealand Clinical Trials Registry (ACTRN12609000259246).
Participant recruitment
Recruitment targeted individuals who had symptomatic COPD
with stable persistent neutrophilic bronchitis. Adults (males and
non-pregnant females) who were more than 55 years of age with a
doctors diagnosis of symptomatic COPD (n = 77) were recruited
from a tertiary care setting at the Respiratory and Sleep Medicine
Ambulatory Care Service, John Hunter Hospital, NSW, Australia.
Inclusion criteria were a post bronchodilator FEV1/FVC ,70%
and FEV1,80% [14] and persistent neutrophilic bronchitis
defined as sputum neutrophil proportion of more than 61% or
more than 1626104/mL sputum neutrophils demonstrated on two
occasions (at least one being the screening visit). The neutrophil
cut-off were based upon the upper limit of normal from healthy
controls [15]. Participants had no reported exacerbations or
alterations in respiratory medications in the previous 4 weeks.
Additional exclusion criteria were the inability to produce an
adequate sputum sample, a FEV1,0.5 L, current smoking or
having ceased smoking in the past 6 months, a known
hypersensitivity to macrolides, an ECG assessment showing a
prolonged QTc interval $440 msec or an impairment of liver
function.
Following screening, 17 participants were excluded as they did
not meet the lung function criteria, 16 did not meet the
neutrophilic inflammation criteria, 3 were excluded as they did
not meet the QTc or LFT criteria to enter the randomised
controlled trial of azithromycin and 4 were unable to produce
sufficient sputum. A further 7 participants declined to participate
following screening (Figure 1).
Eligible participants (n = 30) were randomly allocated (1:1) to
receive oral azithromycin 250 mg daily or identical placebo for 12
weeks. Both participants and study staff were blinded to the
assignment of intervention. In addition to the screening visit,
randomised participants attended 4 visits at monthly intervals with
the final study visit conducted 4 weeks after the end of treatment.
Concealed random allocation was undertaken by a blinded staff
member who took no further part in the study (HP). A random
numbers table was computer generated (www.randomization.com)
for treatment allocation using permuted blocks of six and
participants were stratified according to smoking history (never
or previous smokers). The active medication and placebo were
prepared and packaged identically by a compounding chemist
(Stenlake Science and Nature, Bondi Junction, NSW, Australia)
and dispensed by the John Hunter Hospital pharmacy according
to the random number table. After 12 weeks of treatment,
participants were followed for an additional 12 weeks by monthly
telephone interview and any changes in respiratory health
recorded.
Assessments
At screening (visit 1), pre and post bronchodilator spirometry,
skin allergy prick testing, medication history, smoking status and
exhaled carbon monoxide (eCO) were assessed and sputum
induction was undertaken. Single breath diffusing capacity test was
performed in those who had smoked cigarettes for more than 10
pack years (one pack year is approximated to 20 cigarettes daily for
1 year).
At visit 2 (baseline), mucus hypersecretion, St George Respira-
tory Questionnaire (SGRQ) [16], symptom visual analogue scores
(VAS), Clinical COPD Questionnaire (CCQ) [17], modified
Medical Research Council (mMRC) dyspnoea scale, sputum and
blood were collected. Sputum was processed for inflammatory cell
counts and supernatant stored for the assessment for inflammatory
mediators.
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A chest CT scan was performed in a subgroup of 15 participants
as a secondary exploratory analysis.
Health care utilisation and quality of life. Health care
utilisation was assessed by asking participants about their visits to
hospital, emergency room and General Practitioner due to their
chest disease and about courses of oral corticosteroids or
antibiotics for their disease in the past 12 months. Quality of life
was assessed using the SGRQ.
Mucus production and chronic bronchitis. Mucus pro-
duction was noted as positive if the participant reported an
affirmative answer to the following questions: ‘Do you cough and
produce sputum/phlegm?’ or ‘Do you usually bring up phlegm
from your chest?’, or ‘Do you usually have phlegm in your chest
that is difficult to bring up when you don’t have a cold?’. The
presence of chronic bronchitis was assessed using questions taken
from the American Thoracic Society and Division of Lung
Diseases respiratory symptom questionnaire [18].
Smoking assessment. A smoking history was taken and
smoking pack-years determined. Participants underwent eCO
measurements, determined by electrochemical detection with a
Smokerlyzer (Bedfont Scientific, Kent, UK; detection limit of
1 ppb). All included participants had an eCO of less than 10 ppm
confirming their non-smoking status [19].
Figure 1. Participant consort diagram.
doi:10.1371/journal.pone.0105609.g001
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Severe exacerbations. A severe exacerbation was defined as
an increase in symptoms requiring unscheduled medical attention
and the use of oral corticosteroids and/or antibiotic treatment
[20].
Pulmonary function tests. Three reproducible measure-
ments of forced expiratory volume in 1 second (FEV1) and forced
vital capacity (FVC) were obtained (KoKo, PD Instrumentation,
Louisville, CO, USA) before and after inhalation of 200 mg
salbutamol via a metered dose inhaler with valved holding
chamber (Volumatic, Allen and Hanbury’s, Australia). These
measures were compared to predicted values according to
Knudson et al., [21]. The carbon monoxide transfer co-efficient
(KCO) was determined according to ATS guidelines (Med-
Graphics Elite DX, Medical Graphics Corporation, St Paul,
MN, USA) [22].
Chest computed tomography. CT scans were acquired
using a multi-slice CT scanner (Cardiac 64 multi-slice scanner,
Siemens, Forchheim, Germany) at the baseline visit and 4 weeks
following the end of azithromycin treatment. The inspiratory and
expiratory scans were measured using the CT analysis software
Apollo (VIDA Diagnostics, Coralville, IA, USA) and the following
parameters were obtained: total lung volume, mean lung density at
both inspiration and expiration, the percentage of lung with
densities below 2950 Hounsfield units (HU) on inspiration
(emphysema) and 2856 HU on expiration (air trapping). The
three-dimensional reconstruction of the airway tree was used to
measure the airway lumen and wall area at the midpoint between
airway junctions in all airways from the 3rd generation (segmental
airways) to the 5th generation. Using these data the square root of
wall area of all these bronchi were plotted against the internal
perimeter for each subject. Individual regression equations were
used to calculate the square root of the airway wall area for an
idealized airway with an internal diameter of 10 mm. This
parameter was chosen because it has been shown to predict the
mean dimensions of histological small airways in COPD. Scans
were also scored independently by a thoracic specialist radiologist
(DGM) blinded to the subject group using a modified Bhalla
scoring system as previously described [23].
Sputum induction, analysis and bacterial culture. Sputum
was induced with hypertonic saline (4.5%) as previously described
[24]. Selected sputum was dispersed using dithiothreitol (DTT).
Sputum dispersed in DTT was diluted serially into skim milk powder,
tryptone soya powder, glycerol and glucose (STGG) media [25] and
chocolate bacitracin and blood agar plates were inoculated (10 mL)
and incubated for 48 hours at 37uC, 5% CO2. Bacterial colonies
were enumerated, cfu/mL calculated and sub-cultured for identifi-
cation [3,26]. Identification included Gram stain, oxidase and
catalase testing, Haemophilus identification plates, staphylase and
tributyrin tests.
A total cell count of leucocytes and viability was performed on
filtered suspensions. Following centrifugation, supernatant was
stored at 280uC. Cytospins were prepared, stained (May-
Grunwald Geimsa) and a differential cell count obtained from
400 non-squamous cells. Supernatants were stored for the
assessment of CXCL8 and neutrophil elastase (NE). CXCL8 was
assessed using a commercial ELISA kit (R&D Systems, Minneap-
olis, MN, USA) and NE was measured with the InnoZyme
Human Neutrophil Elastase Immunocapture Activity Assay
(Calbiochem, Merck, Kilsyth, Victoria, Australia).
Adverse events. Adverse events including the presence of
fever, headache, nausea, vomiting, diarrheoa and skin rashes were
recorded at each study visit and at fortnightly intervals between
study visits.
Statistical methods. Statistical analysis was performed using
Stata 11 (StataCorp, College Station, TX, USA). Results are
presented as mean 6 standard deviation (SD) or median
(interquartile range (IQR)) with Student’s t-test for parametric
data and Wilcoxon rank-sum tests for nonparametric data. Paired
data were analysed using the Wilcoxon signed-rank test. Categor-
ical data were compared using the Chi-square or Fisher’s exact test
as appropriate. Two-sided tests with p values ,0?05 were
considered significant. The primary outcome variable of this
study was a reduction in sputum CXCL8; secondary outcome
variables were change in sputum neutrophil proportion and total
bacterial load. This study was powered to detect a change of
250 pg/mL in CXCL8 based on a previous randomised controlled
trial of macrolide therapy in COPD [27]. Exacerbation data were
analysed on an intention-to-treat basis. A Poisson regression model
was used to compare the exacerbation rate difference between the
treatment groups. The time to first exacerbation was analysed
using Kaplan-Meier plots and analysis of instantaneous risk
described using a Cox proportional hazards model. Analysis of
covariance was conducted on end of study QoL and sputum
variables with adjustment for baseline values. Other continuous
variables such as symptoms were analysed using a generalised
linear mixed model with a random intercept for individuals to
account for the repeated measurements on individuals.
Results
Patient participation
Seventy-seven patients were screened for the study between
April 2009 and December 2011. Thirty eligible participants (19
male, Figure 1) underwent detailed clinical and inflammatory
assessment and subsequent random allocation to treatment (15 to
azithromycin and 15 to placebo). Twenty eight entered the follow-
up period, 2 did not complete the 12 week treatment as they were
excluded (Figure 1). Analyses of the effects of treatment were
performed on 30 participants (19 male) who completed the study
(Table 1).
The included participants had a mean age of 71 years and 22
(73%) had smoked previously with a median of 46 pack years.
Eleven participants had a smoking history of more than 10 pack
years and this group had a mean (q1,q3) KCO% predicted of 62
(49,84). Nineteen participants (63%) had airflow limitation of
moderate severity according to the Global initiative for chronic
Obstructive Lung Disease (GOLD) guidelines [28]. Using the most
recent descriptors for GOLD severity categories which incorporate
the mMRC score and exacerbation history, 21 (70%) participants
with neutrophilic COPD were categorised as high risk (Quadrant
C-17 participants and Quadrant D-4 participants), with the
remaining 9 (30%) participants were designated as low risk, 7 with
low symptoms and 2 with high symptoms (Quadrant A and B
respectively) [28]. At each visit a sputum sample was attempted for
each of the 30 participants; of the 150 attempts, 135 had a sputum
sample collected (90%) and an adequate sputum sample was
produced on 122 occasions (90%).
Participants had significant neutrophilia (median 66% sputum
neutrophils). At randomisation, 25 participants had culture results,
9 with potentially pathogenic bacteria. The most common bacteria
cultured was Pseudomonas aeruginosa (n = 4) and Streptococcus
pneumoniae (n = 2), Haemophilus influenzae (n = 1), Moraxella
cattarhalis (n = 1) and Staphylococcus aurerus (n = 1).
Response to azithromycin
There were no significant differences between treatment groups
at baseline with respect to age, gender, atopy, lung function,
Azithromycin in COPD with Neutrophilic Bronchitis
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Table 1. Participant characteristics.
All participants Placebo Azithromycin p value
N 30 15 15
Clinical parameters
Age, mean (SD); range 70.8 (7.6) 69.9 (8.9) 71.7 (6.2) 0.535
Sex, Male/Female 19/11 10/5 9/6 0.705
Ex-smokers, n (%) 22 (73.3%) 11 (73.3) 11 (73.3) 1.0
Pack years, mean (SD) 46.11 (36.61) 56.2 (43.2) 36.0 (26.9) 0.202
FEV1% predicted, mean (SD) 53.69 (13.74) 51.1 (13.7) 56.5 (13.7) 0.297
FEV1/FVC, mean (SD) 57.79 (11.24) 51.3 (11.3) 52.3 (11.6) 0.811
Atopy, n (%) 14 (46.67%) 8 (53.3) 6 (40.0) 0.464
ICS dose, BDP equivalent, mg/day, mean (range) 1011, (400–2000) 800 (500–1000), N = 15 1000 (800–2000), N = 11 0.196
CCQ total score, mean (SD) 16.0 (17.6) 16.5 (6.97) 15.4 (8.47) 0.692
SGRQ total score, mean (SD) 34.2 (16.0) 33.8 (15.7) 34.5 (16.8) 0.907
mMRC dyspnea score, mean (SD) 0.90 (0.80) 0.87 (0.92) 0.93 (0.70) 0.825
Inflammatory outcomes
Total cell count, 6106/mL, median (q1,q3) 5.54 (3.78,9.54) 5.58 (3.78,9.54) 4.68 (3.33,10.71) 0.604
Viability, %, median (q1,q3) 88.0 (78.5,92.5) 87.12 (73.9,92.86) 88.4 (78.99,92.5) 0.788
Neutrophils, %, median (q1,q3) 65.63 (46.5,71.25) 68 (46.5,82.3) 63.5 (42.75,71.0) 0.547
Neutrophils, 6104/mL, median (q1,q3) 368.9 (209.3,556.9) 380.4 (209.3,556.9) 251.5 (165.4,570.7) 0.468
Eosinophils, %, median (q1,q3) 2.03 (1.25,3.50) 1.75 (1.25,3.0) 3.25 (1.25,8.0) 0.140
Eosinophils, 6104/mL, median (q1,q3) 10.85 (5.74,30.07) 10.2 (4.3,18.5) 16.1 (5.7,69.0) 0.468
Macrophages, %, median (q1,q3) 31.63 (19.0,43.75) 30.25 (15.1,46.5) 32.5 (21.5,43.75) 0.885
Macrophages, 6104/mL, median (q1,q3) 171.7 (117.0,248.0) 209.3 (140.0,289.7) 130.7 (88.7,205.7) 0.152
Lymphocytes, %, median (q1,q3) 0.25 (0,1.25) 0.25 (0,1.75) 0.5 (0,0.75) 0.470
Lymphocytes, 6104/mL, median (q1,q3) 2.57 (0,6.46) 3.7 (0,9.0) 1.2 (0,5.7) 0.197
Columnar epithelials, %, median (q1,q3) 0.5 (0,1.75) 0.5 (0,2.25) 0.5 (0,1.25) 0.525
Columnar epithelials, 6104/mL, median (q1,q3) 2.30 (0,5.36) 2.5 (0,13.5) 1.6 (0,5.0) 0.460
Squamous, %, median (q1,q3) 16.33 (9.17,41.73) 5.88 (0.74,11.31) 3.14 (1.48,6.54) 0.694
CXCL8, ng/mL, median (q1,q3) 16.22 (8.50,32.93) 25.37 (10.32,58.88) 11.93 (6.19,21.93) 0.120
NE, ng/mL, median (q1,q3) 3038 (1318,6872) 3868 (1722,10272) 1950 (901.3,4756) 0.141
Bacteriology N = 26 N = 14 N = 14
Bacterial load, 6107 cfu/mL, median (q1,q3) 7.01 (1.84,14.5) 6.55 (1.84,14.00) 5.02 (1.65,20.0) 0.783
Bacterial pathogen isolated, n (%) 9 (37%) 3 (23%) 6 (46%) 0.205
Computed tomography
Quantitative scores N = 14 N = 7 N = 7
Inspiratory lung density, mean (SD) 2856.82 (22.07) 2844.55 (23.14) 2869.08 (12.99) 0.031
% below 2950 HU, inspiratory, mean (SD) 14.53 (9.86) 11.96 (9.66) 17.09 (10.10) 0.351
% below 2856 HU, inspiratory, mean (SD) 64.73 (8.90) 58.95 (8.81) 70.52 (3.97) 0.008
Expiratory/Inspiratory mean lung density, mean (SD) 0.92 (0.04) 0.92 (0.05) 0.93 (0.03) 0.536
Inspiratory PI, mm, mean (SD) 3.82 (0.07) 3.84 (0.10) 3.80 (0.05) 0.459
Expiratory PI, mm, mean (SD) 3.94 (0.12) 3.94 (0.17) 3.95 (0.09) 0.902
Qualitative scores N = 17 N = 9 N = 6
Extent of bronchiectasis score, median (q1,q3) 1.0 (0.0,5.5) 5 (1.0,8.0) 0.5 (0.0,2.0) 0.160
Severity of bronchiectasis score, median (q1,q3) 1.0 (0.0,3.5) 3.0 (1.0,5.0) 0.5 (0.0,2.0) 0.160
Bronchial wall thickness score, median (q1,q3) 3.0 (2.0,4.5) 3 (3,5) 2 (0,4) 0.204
Bronchial wall thickness .2, n (%) 2.0 (12.0%) 2 (20%) 0 (0%) 0.331
Total lung score, median (q1,q3) 5.5 (4.0,12.0) 9 (4,16) 5 (0,6) 0.102
Total emphysema score, median (q1,q3) 0.0 (0.0,20.0) 2.1 (0.0,23.3) 0.0 (0.0,20.0) 0.673
Number of lobes decreased attenuation .0, median (q1,q3) 5.0 (3.0,6.0) 5 (4,6) 3 (2,5) 0.088
Mucus plugging (large or small airways), n (%) 2.0 (12.0%) 2 (20%) 0 (0%) 0.331
Consolidation present in any lobe, n (%) 5.0 (29.4%) 2 (20%) 3 (43%) 0.314
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quality of life, or daily inhaled corticosteroid (ICS) dose (Table 1).
At baseline there were significantly more gas trapping in those
treated with azithromycin compared to placebo (Table 1). There
was a non-significant reduction in sputum neutrophil proportion,
levels of CXCL8 and airway bacterial load in those who received
add-on azithromycin compared to placebo shown in Figure 2.
There were no differences in symptom score, SGRC, CCQ, lung
function and CT scores at the end of treatment comparing
azithromycin to placebo despite correction for baseline variation
(Table 2).
Twenty-two participants had samples for bacterial culture at
randomisation and end of treatment visits, of which 10 had no
identifiable pathogen at both visits (43%). Three participants had
Pseudomonas aeruginosa identified at both visits (2 from the AZM
and 1 from the Placebo group). Of the remaining participants with
paired culture results, 5/9 were culture positive at randomisation
(3 AMZ, 2 placebo) and negative at the end of the study, 4/9 were
culture negative at randomisation and culture positive at the end
of treatment (2 AZM and 2 placebo).
The total bacterial load was reduced by 53% following AZM
treatment from 5.026107 cfu/mL to 2.376107 cfu/mL. In the
placebo group there was also a reduction in total bacterial load of
37% from a median of 6.556107 cfu/mL to 4.146107 cfu/mL.
We assessed the bacterial load of all bacteria identifiable in the
samples and found similar total bacterial loads as to those reported
by Wilkinson et al. [29]. We then selected a cut point of .108 cfu/
mL to define those patients who had a high bacterial load and
found there were 10 participants with high bacterial load who had
paired data pre and post treatment (5 AZM and 5 placebo). There
was no difference in neutrophil proportion or CXCL8 levels
following add-on azithromycin treatment in those with a high
bacterial load. The bacterial load did reduce by 10 fold but this
was not statistically significant, shown in Table 3.
There was a clinically significant reduction in the median
number of severe exacerbations experience by those treated with
add-on azithromycin compared to placebo. With azithromycin,
the median (IQR) number of severe exacerbations experienced
was 0 (0,1), which was significantly less than with placebo (1 (0,2);
p = 0.046). The mean severe exacerbation rate was 0.33 exacer-
bations per person per 26 weeks in the azithromycin group
compared to 0.93 exacerbations per person in the placebo group
(incidence rate ratio (95%CI): 0.38 (0.14,1.05, p = 0.062)). Fewer
participants in the azithromycin group experienced a severe
exacerbation, 4 (26.7%) compared to 9 (60%) in the placebo group
(p = 0.139). The azithromycin group were 63% less likely to
exacerbate at any time point (hazards ratio (95%CI): 0.37
(0.11,1.21), p = 0.100, Figure 3).
The most common macrolide-related side effect reported was
diarrhoea in 5 participants taking azithromycin and 1 participant
taking placebo. In all cases the side effect did not cause the
participant to cease study medication or withdraw from the study
(Table 4).
Discussion
Participants with symptomatic COPD and stable neutrophilic
bronchitis exhibited typical features of COPD including a previous
history of cigarette smoking, presence of potentially pathogenic
bacteria and health care utilisation for exacerbations. Twelve
weeks of add-on azithromycin resulted in a clinically significant
reduction in severe exacerbations and a non-significant reduction
in neutrophilic airway inflammation, sputum CXCL8 levels and
bacterial load.
These findings suggest that the exacerbation-reducing effects of
macrolides in COPD shown in a recent meta-analysis [30] may
not due to reductions in neutrophilic inflammation or bacterial
load, as seen in individuals with cystic fibrosis and diffuse
panbronchiolitis. This kind of heterogeneity in the response to
macrolides is similar to that observed in participants with diffuse
panbronchiolitis and small airways disease, where clinical
improvements were observed in both groups but only those with
diffuse panbronchiolitis had reductions in neutrophils [31]. The
BDP equivalent: dose of inhaled corticosteroids is calculated as beclomethasone equivalents where 1 mg of beclomethasone = 1 mg budesonide = 0.5 mg fluticasone;
CCQ: Clinical COPD Questionnaire; SGRQ: St George Respiratory Questionnaire; mMRC: modified Medical Research Council; cfu: colony-forming units; PI: Internal
perimeter.
doi:10.1371/journal.pone.0105609.t001
Figure 2. Bar graphs showing the change in sputum neutrophil%, IL-8 ng/mL and total bacterial load following treatment with
azithromycin (AZM) or placebo.
doi:10.1371/journal.pone.0105609.g002
Azithromycin in COPD with Neutrophilic Bronchitis
PLOS ONE | www.plosone.org 6 August 2014 | Volume 9 | Issue 8 | e105609
Table 2. End of treatment clinical and inflammatory outcomes.
Placebo Azithromycin p value p value
Clinical outcomes N = 15
FEV1% predicted, mean (SD) 52.17 (14.3) 57.79 (13.90) 0.285 0.748
¥
FEV1/FVC, mean (SD) 50.19 (10.33) 54.70 (13.03) 0.409 0.136
¥
CCQ total score, mean (SD) 15.1 (9.2) 16.9 (10.1) 0.614 0.329#
SGRQ total score, mean (SD) 28.1 (13.2) 34.2 (15.9) 0.259 0.098#
mMRC dyspnea score, median (q1,q3) 1 (0,1) 1 (0,2) 0.695 1.000#
VAS Breathlessness, median (q1,q3) 27 (0,43) 27 (7,68) 0.676 0.101#
VAS Wheeze, median (q1,q3) 2 (0,31) 2 (0,28) 0.829 0.751#
VAS Cough, median (q1,q3) 18 (8,42) 14 (0,63) 0.868 0.380#
VAS Chest tightness, median (q1,q3) 5 (0,31) 8 (0,31) 0.542 0.937#
Inflammatory outcomes N = 15 N = 15
Total cell count, 6106/mL, median (q1,q3) 4.32 (2.25,7.38) 3.96 (1.89,8.73) 0.787 0.862#
Viability, %, median (q1,q3) 77.5 (75.0,91.29) 85.7 (63.8,94.03) 0.663 0.946#
Neutrophils, %, median (q1,q3) 60.0 (42.25,82.75) 61.63 (56.5,78.5) 0.627 0.695#
Neutrophils, 6104/mL, median (q1,q3) 372.4 (223.7,459.0) 186.8 (122.7,470.9) 0.577 0.578#
Eosinophils, %, median (q1,q3) 1.25 (1.0,2.5) 3.0 (0.5,7.25) 0.527 0.466#
Eosinophils, 6104/mL, median (q1,q3) 7.88 (3.83,15.98) 10.52 (1.62,31.68) 0.884 0.251#
Macrophages, %, median (q1,q3) 34.75 (12.75,41.4) 32.25 (19.0,38.75) 1.000 0.810#
Macrophages, 6104/mL, median (q1,q3) 109.15 (76.68,225.68) 99.14 (65.61,227.12) 0.734 0.897#
Lymphocytes, %, median (q1,q3) 0.5 (0.25,1.0) 0.25 (0,0.5) 0.156 0.113#
Lymphocytes, 6104/mL, median (q1,q3) 2.16 (1.13,6.68) 0.64 (0,4.10) 0.125 0.339#
Columnar epithelial cells, %, median (q1,q3) 1.2 (0,2.25) 0.25 (0,1.5) 0.416 0.887#
Columnar epithelial cells, 6104/mL, median (q1,q3) 6.38 (0,10.48) 1.62 (0,4.32) 0.523 0.690#
CXCL8, ng/mL, median (q1,q3) 33.0 (5.95,57.38) 9.22 (4.97,41.03) 0.310 0.825#
NE, ng/mL, median (q1,q3) 3977.4 (435.8,8182.1) 1496.2 (564.3,5408.9) 0.468 0.470#
Bacteriology N = 13 N = 13
Bacterial load, 6107 cfu/mL, median (q1,q3) 5.10 (3.29,33.0) 2.37 (1.65,15.5) 0.285 0.755#
Pathogen isolated, n (%) 3 (23%) 5 (35%) 0.336
Computed tomography
Quantitative scores N = 5 N = 6
Inspiratory lung density, mean (SD) 2853.52 (30.30) 2865.75 (17.30) 0.403 0.966#
% below 2950 HU, inspiratory, mean (SD) 15.51 (11.55) 14.81 (8.37) 0.904 0.947#
% below 2856 HU, inspiratory, mean (SD) 62.19 (12.60) 69.52 (7.98) 0.246 0.891#
Expiratory/Inspiratory mean lung density, mean (SD) 0.92 (0.05) 0.92 (0.02) 0.938 0.902#
Inspiratory PI, mm, mean (SD) 3.84 (0.05) 3.83 (0.04) 0.698 0.875#
Expiratory PI, mm, mean (SD) 3.93 (0.17) 3.91 (0.10) 0.797 0.224#
Qualitative scores N = 9 N = 5
Extent of bronchiectasis score, median (q1,q3) 5 (1,8) 0 (0,1) 0.086 0.971#
Severity of bronchiectasis score, median (q1,q3) 3 (1,5) 0 (0,1) 0.086 0.775#
Bronchial wall thickness score, median (q1,q3) 4 (3,5) 1 (0,30) 0.092 0.793#
Bronchial wall thickness score .2, n (%) 2 (100%) 0 (0%) 0.486
Total lung score, median (q1,q3) 11 (6,17) 5 (0,5) 0.038 0.754#
Total emphysema score, median (q1,q3) 0 (0,23.33) 0 (0,6.67) 0.425 0.696#
Number of lobes decreased attenuation .0, median (q1,q3) 5 (4,6) 3.5 (3,4) 0.114 0.599#
Mucus plugging (large or small airways), n (%) 3 (75%) 1 (25%) 0.604
Consolidation present in any lobe, n (%) 2 (40%) 3 (60%) 0.329
¥GLMM: Generalised Linear Mixed Model; #ANCOVA: adjusted for baseline and robust option for non-parametric data; CCQ: Clinical COPD Questionnaire; SGRQ: St
George Respiratory Questionnaire; mMRC: modified Medical Research Council; VAS: visual analogue scale; cfu: colony-forming units; PI: Internal perimeter.
doi:10.1371/journal.pone.0105609.t002
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study of Albert and colleagues elegantly show the improvement in
exacerbation rate and health status in COPD, however they did
not assess changes in airway inflammation. Interestingly, the post-
hoc analysis from the largest randomised controlled trial of
macrolides in COPD reported participants with least severe
disease and those who were not taking inhaled corticosteroids,
macrolides had a more favourable effect in reducing exacerba-
tions[13], suggesting that in COPD macrolides may be most
effective in those with more mild disease. In this study, most
participants had moderately severe COPD and 90% were taking
inhaled corticosteroids.
The lack of significance observed in the inflammatory outcomes
may be due to insufficient numbers of patients randomised. We
assessed the possibility of a type 2 error to explain the lack of
significant changes in sputum neutrophils with azithromycin
treatment and found there was sufficient power (0.819) to detect
an effect of azithromycin on neutrophils if one were present. A
previous trial of azithromycin for non-eosinophilic/neutrophilic
airways disease [32] found a reduction in neutrophils of
0.5976106 neutrophils/mL. Our trial had a power of 82% (alpha
0.05) to detect this effect. Since an effect was not observed, it
suggests azithromycin reduces severe exacerbations in neutrophilic
COPD by other means. Alternative mechanisms may include
prevention of bacterial infection-induced exacerbations, reduc-
tions in other inflammatory responses [33], or a synergistic
symptom-controlling mechanism with other respiratory medica-
tions that is not through reductions in inflammation.
In previous studies, addition of clarithromycin to inhaled
corticosteroid therapy resulted in a small but significant reduction
in neutrophil proportion but no change in neutrophil number or of
CXCL8 levels [34]. Other studies showed a significant reduction
the number of neutrophils and levels of NE using erythromycin
three times daily at both 3 and 6 month treatment end points [35]
and a 12 month treatment study with twice daily erythromycin
failed to reduce neutrophil numbers or CXCL8 levels [36].
An alternative explanation for the lack of reduction in
neutrophilic inflammation in our study could be the type of
macrolide used. We selected azithromycin due to its long half-life,
fewer side effects and once daily dosing as particularly suitable for
patients with COPD. A recent study of the efficacy of macrolide
Table 3. Sputum neutrophil proportion, CXCL8 levels and bacterial load before and following add-on azithromycin therapy in
those participants with a high bacterial load (.108 cfu/mL) at baseline.
Visit 2 Visit 5 p value
N = 5 N = 5
Sputum neutrophil, % 71.0 (60.75,75.0) 77.25 (57.5,78.5) 0.893
CXCL8, ng/mL 26.62 (21.94,34.99) 25.42 (24.82,41.03) 0.686
Bacterial load, 6107 cfu/mL 21.9 (20,22) 1.79 (1.65,10.1) 0.225
doi:10.1371/journal.pone.0105609.t003
Figure 3. Kaplan-Meier curves showing the proportion of participants without a COPD exacerbation versus the days post
randomisation visit (p = 0.100).
doi:10.1371/journal.pone.0105609.g003
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antibiotics to inhibit inflammatory cytokine production by COPD
sputum cells showed that clarithromycin and roxithromycin were
more potent than azithromycin [37]. This may explain why the
two studies that used clarithromycin in COPD showed reductions
in neutrophils [34,38].
This study also assessed high resolution chest computed
tomography scans in a sub-group of 17 participants, of which 14
had paired data before and after azithromycin add-on therapy. At
baseline there appeared to be more gas trapping in the group that
went on to receive treatment with azithromycin compared to the
group who was to receive the placebo treatment. However at the
end of treatment after correcting for baseline data there was no
difference in any of the CT scores. As this analysis was only
performed on a small number of participants’, further research is
necessary to determine if add-on azithromycin therapy in COPD
alters gas trapping and other airway scores.
In conclusion, we have characterised and investigated add-on
azithromycin therapy in participants with neutrophilic COPD.
Add-on azithromycin therapy demonstrated a trend for a
reduction in the number of severe exacerbations experienced
and in the markers of neutrophilic airway inflammation. This
study has not identified the mechanism by which azithromycin
leads to reduced exacerbations, however, it suggests that the anti-
exacerbation effect of add-on azithromycin in COPD may not be
through an anti-neutrophilic mechanism. Further work is needed
to determine the mechanism that leads to reduced exacerbations
and a study with a larger sample size is warranted and can be
designed using the data from this report.
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